Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 12/2017

01-12-2017 | Systemic Lupus Erythematosus (G Tsokos, Section Editor)

Renal Macrophages and Dendritic Cells in SLE Nephritis

Authors: Naomi I. Maria, Anne Davidson

Published in: Current Rheumatology Reports | Issue 12/2017

Login to get access

Abstract

Purpose of Review

The purpose of the study was to review the characteristics of renal macrophages and dendritic cells during homeostasis and disease, with a particular focus on lupus nephritis.

Recent Findings

Resident renal macrophages derive from embryonic sources and are long-lived and self-renewing; they are also replaced from the bone marrow with age. The unique characteristics of macrophages in each tissue are imposed by the microenvironment and reinforced by epigenetic modifications. In acute renal injury, inflammatory macrophages are rapidly recruited and then replaced by those with a wound healing/resolution phenotype. In lupus nephritis, dendritic cells infiltrate the kidneys and function to present antigen and organize tertiary lymphoid structures that amplify inflammation. In addition, both infiltrating and resident macrophages contribute to ongoing injury. These cells have a mixed inflammatory and alternatively activated phenotype that may reflect failed resolution, potentially leading to tissue fibrosis and irreversible damage.

Summary

A further understanding of the renal inflammatory cells that mediate tissue injury and fibrosis should lead to new therapies to help preserve renal function in patients with lupus nephritis.
Literature
1.
Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33:643–75.CrossRefPubMed
2.
•• Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541–66. This recent review highlights current knowledge of macrophage polarization, heterogeneity, and plasticity, and how macrophage polarization regulates the physiology of normal and damaged tissues.CrossRefPubMed
3.
Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14(6):392–404.CrossRefPubMed
4.
•• Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375–86. This study describes the patrolling behavior of CD14dim monocytes, and how they produce inflammatory cytokines through sensing of nucleic acids by TLR7 and TLR8. This represents a useful cellular target in select inflammatory and autoimmune diseases.CrossRefPubMedPubMedCentral
5.
•• Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335). Using an unbiased single-cell RNA-sequencing strategy, this study profiles blood from healthy donors and discovers novel DC and monocyte subsets that revise the taxonomy.
6.
•• Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79–91. This study uses CX3CR1 reporter mice to map the murine mononuclear phagocyte compartment, demonstrating that most tissue macrophages are established before birth, independent of adult monocyte input.CrossRefPubMed
7.
Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86–90.CrossRefPubMed
8.
• Perdiguero EG, Geissmann F. The development and maintenance of resident macrophages. Nat Immunol. 2016;17(1):2–8. This review discusses current knowledge on macrophage development and highlights resident macrophages generated in the yolk sac to be distinct from passenger macrophages and myeloid cells that originate and renew from the bone marrow.CrossRefPubMedPubMedCentral
9.
10.
•• Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159(6):1327–40. This study shows how specific tissue environments drive distinct gene expression profiles by activation of a tissue-specific enhancer repertoire, thereby influencing macrophage phenotypes.CrossRefPubMedPubMedCentral
11.
12.
•• Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159(6):1312–26. This is the first study to describe the epigenetic profile of tissue-resident macrophages, and how this is shaped by the local microenvironment.CrossRefPubMedPubMedCentral
13.
• Amit I, Winter DR, Jung S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat Immunol. 2016;17(1):18–25. This review discusses the role the local microenvironment plays in shaping tissue-macrophage identity.CrossRefPubMed
14.
• Glass CK, Natoli G. Molecular control of activation and priming in macrophages. Nat Immunol. 2016;17(1):26–33. This review highlights recent findings on mechanisms underlying signal-dependent activation and priming of macrophages and discusses the impact of genetic variation on these processes.CrossRefPubMed
15.
•• Sahu R, Bethunaickan R, Singh S, Davidson A. Structure and function of renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol. 2014;66(6):1596–607. Here, our group highlights the heterogeniety of renal macrophage/DC infiltrates in chronic lupus nephritis in a mouse model and provides an initial phenotypic and functional analysis that aids in defining the roles for each subset in nephritis.CrossRefPubMedPubMedCentral
16.
• Kawakami T, Lichtnekert J, Thompson LJ, Karna P, Bouabe H, Hohl TM, et al. Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions. J Immunol. 2013;191(6):3358–72. This study defines five disctinct resident renal mononuclear phagopcyte subpopulations in the normal mouse kidney using an array of surface markers, which goes beyond the conventional classification.CrossRefPubMed
17.
• Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011;186(8):4994–5003. In this study, our group describes a unique renal mononuclear phagocyte that contributes to tissue damage in lupus nephritis by mediating both local inflammation and excessive tissue remodeling.CrossRefPubMedPubMedCentral
18.
Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62(5):1457–68.CrossRefPubMedPubMedCentral
19.
Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, et al. The heterogeneity of Ly6Chi monocytes controls their differentiation into iNOS+ macrophages or monocyte-derived dendritic cells. Immunity. 2016;45(6):1205–18.CrossRefPubMedPubMedCentral
20.
Goudot C, Coillard A, Villani AC, Gueguen P, Cros A, Sarkizova S, et al. Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages. Immunity. 2017;47(3):582–596.e6.
21.
•• Huen SC, Cantley LG. Macrophages in renal injury and repair. Annu Rev Physiol. 2017;79:449–69. This recent review highlights current understanding of how macrophages mechanistically contribute to injury and repair in acute kidney injury (AKI).CrossRefPubMed
22.
Mildner A, Schonheit J, Giladi A, David E, Lara-Astiaso D, Lorenzo-Vivas E, et al. Genomic characterization of murine monocytes reveals C/EBPbeta transcription factor dependence of Ly6C- cells. Immunity. 2017;46(5):849–862.e7.
23.
• Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666–70. This seminal study establishes our knowledge of the patrolling behavior of Ly6C lo monocytes and describes the functional differences between the monocyte subsets.CrossRefPubMed
24.
•• Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G, et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell. 2013;153(2):362–75. This study describes recruitment of patrolling Ly6C low monocytes to the endothelium and into the kidneys and shows that this is dependent on TLR7 expression in renal cells.CrossRefPubMedPubMedCentral
25.
Quintar A, McArdle S, Wolf D, Marki A, Ehinger E, Vassallo M, et al. Endothelial protective monocyte patrolling in large arteries intensified by western diet and atherosclerosis. Circ Res. 2017;120(11):1789–99.CrossRefPubMedPubMedCentral
26.
Williams JW, Randolph GJ, Zinselmeyer BHA. Polecat’s view of patrolling monocytes. Circ Res. 2017;120(11):1699–701.CrossRefPubMed
27.
Celhar T, Pereira-Lopes S, Thornhill SI, Lee HY, Dhillon MK, Poidinger M, et al. TLR7 and TLR9 ligands regulate antigen presentation by macrophages. Int Immunol. 2016;28(5):223–32.CrossRefPubMed
28.
• Yoshimoto S, Nakatani K, Iwano M, Asai O, Samejima K, Sakan H, et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis. 2007;50(1):47–58. This study describes the association of SLE disease severity with glomerular fractalkine expression and CD16 + /CX3CR1 + monocyte accumulation in humans.CrossRefPubMed
29.
•• Stamatiades EG, Tremblay ME, Bohm M, Crozet L, Bisht K, Kao D, et al. Immune monitoring of trans-endothelial transport by kidney-resident macrophages. Cell. 2016;166(4):991–1003. This study identifies the unique immune monitoring property of kidney macrophages and a mechanism by which they initiate inflammatory responses to small immune complexes in the kidney.CrossRefPubMedPubMedCentral
30.
•• Kassianos AJ, Wang X, Sampangi S, Muczynski K, Healy H, Wilkinson R. Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(10):F1391–401. This study identifies activated mDC subsets to be positioned strategically, after being recruited to the tubulointerstitium, to play a role in the development of fibrosis and thereby contribute to renal fibrosis and chronic kidney disease.CrossRefPubMed
31.
•• Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–88. This study proposes a refined activation-independent core signature for human and murine macrophages, and reveals a spectrum of macrophage activation states extending beyond the current M1 vs. M2 polarization model, identifying central transcriptional regulators associated with all macrophage activation complemented by regulators related to stimulus-specific programs.CrossRefPubMedPubMedCentral
32.
Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep. 2016;17(3):684–96.CrossRefPubMed
33.
34.
•• Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42(3):419–30. This study provides a comphrehensive view of the integrated transcriptional and central metabolic changes during murine macrophage polarization and uncovers targets for control and intervention of this polarization process.CrossRefPubMed
35.
Phan AT, Goldrath AW, Glass CK. Metabolic and epigenetic coordination of T cell and macrophage immunity. Immunity. 2017;46(5):714–29.CrossRefPubMed
36.
Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, et al. Alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985–94.PubMed
37.
•• O'Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553–65. This review highlights the complex interplay between metabolic reprogramming and immunity and provides a clear overview of our knowledge of immunometabolism to date.CrossRefPubMedPubMedCentral
38.
• Mills EL, Kelly B, Logan A, Costa AS, Varma M, Bryant CE, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167(2):457–70 e13. This study describes how the metabolic alterations that occur upon activation of macrophages repurpose mitochondria from ATP synthesis to ROS production in order to promote a pro-inflammatory state.CrossRefPubMed
39.
Helm O, Held-Feindt J, Schafer H, Sebens S. M1 and M2: there is no “good” and “bad”—how macrophages promote malignancy-associated features in tumorigenesis. Oncoimmunology. 2014;3(7):e946818.CrossRefPubMedPubMedCentral
40.
•• Martinez J, Cunha LD, Park S, Yang M, Lu Q, Orchard R, et al. Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature. 2016;533(7601):115–9. This study identifies a noncanonical authophagic process, LC-3-associated phagocytosis (LAP), in the control of autoinflammatory lupus-like disease and suggests a link between failed clearance of dying cells, LAP, and SLE pathogenesis.CrossRefPubMedPubMedCentral
41.
Martinez J, Malireddi RK, Lu Q, Cunha LD, Pelletier S, Gingras S, et al. Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat Cell Biol. 2015;17(7):893–906.CrossRefPubMedPubMedCentral
42.
43.
•• Gieseck RL, 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2017. This review highlights mechanisms by which type 2 immunity contributes to tissue regeneration and fibrosis following injury, and the involvement of macrophages in the resolution of inflammation and repair.
44.
Hesketh M, Sahin KB, West ZE, Murray RZ. Macrophage phenotypes regulate scar formation and chronic wound healing. Int J Mol Sci. 2017;18(7)
45.
•• Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317–26. This study shows that macrophages can undergo a phenotypic switch from pro-inflammatory to a trophic phenotype that supports the transition from kidney tubular injury to tubule repair/recovery.CrossRefPubMedPubMedCentral
46.
Brandt S, Mertens PR. The kidney regulates regeneration, but don’t upset the balance. Int Urol Nephrol. 2016;48(8):1371–6.CrossRefPubMed
47.
48.
Cao Q, Harris DC, Wang Y. Macrophages in kidney injury, inflammation, and fibrosis. Physiology (Bethesda). 2015;30(3):183–94.
49.
Braga TT, Correa-Costa M, Guise YF, Castoldi A, de Oliveira CD, Hyane MI, et al. MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages. Mol Med. 2012;18:1231–9.CrossRefPubMedPubMedCentral
50.
• Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science. 2017;356(6342):1026–30. This review highlights current knowledge as well as novel concepts of inflammation and cell metabolism in tissue repair, regeneration, and fibrosis, and discusses potential clinical therapeutic approaches to improve wound healing.CrossRefPubMed
51.
Headland SE, Norling LV. The resolution of inflammation: principles and challenges. Semin Immunol. 2015;27(3):149–60.CrossRefPubMed
52.
Lopez-Guisa JM, Cai X, Collins SJ, Yamaguchi I, Okamura DM, Bugge TH, et al. Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol. 2012;23(2):236–51.CrossRefPubMedPubMedCentral
53.
54.
•• Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001;59(1):304–17. This report describes the predictive power of a second (repeat) renal biopsy on risk of progression to renal failure and the association of macrophage with poorer prognosis.CrossRefPubMed
55.
Yang N, Isbel NM, Nikolic-Paterson DJ, Li Y, Ye R, Atkins RC, et al. Local macrophage proliferation in human glomerulonephritis. Kidney Int. 1998;54(1):143–51.CrossRefPubMed
56.
• Dias CB, Malafronte P, Lee J, Resende A, Jorge L, Pinheiro CC, et al. Role of renal expression of CD68 in the long-term prognosis of proliferative lupus nephritis. J Nephrol. 2017;30(1):87–94. This study identifies an association between renal CD68 (macrophage) expression and progression of chronic kidney disease in patients with proliferative lupus nephritis.CrossRefPubMed
57.
Lindenmeyer M, Noessner E, Nelson PJ, Segerer S. Dendritic cells in experimental renal inflammation—part I. Nephron Exp Nephrol. 2011;119(4):e83–90.CrossRefPubMed
58.
Noessner E, Lindenmeyer M, Nelson PJ, Segerer S. Dendritic cells in human renal inflammation—part II. Nephron Exp Nephrol. 2011;119(4):e91–8.CrossRefPubMed
59.
Woltman AM, de Fijter JW, Zuidwijk K, Vlug AG, Bajema IM, van der Kooij SW, et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int. 2007;71(10):1001–8.CrossRefPubMed
60.
• Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol. 2012;189(2):988–1001. This study identifies key shared transcriptional pathways between mouse and human lupus nephrtitis.CrossRefPubMedPubMedCentral
61.
Misharin AV, Cuda CM, Saber R, Turner JD, Gierut AK, Haines GK, 3rd, et al. Nonclassical Ly6C(−) monocytes drive the development of inflammatory arthritis in mice. Cell Rep 2014;9(2):591–604.
62.
• Celhar T, Hopkins R, Thornhill SI, De Magalhaes R, Hwang SH, Lee HY, et al. RNA sensing by conventional dendritic cells is central to the development of lupus nephritis. Proc Natl Acad Sci U S A. 2015;112(45):E6195–E6204. This study highlights the importance of conventional DCs and their RNA-sensing capacities through TLR7 expression for kidney pathogenesis in murine lupus nephritis.
63.
Wolf Y, Shemer A, Polonsky M, Gross M, Mildner A, Yona S, et al. Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation. J Exp Med. 2017;214(4):905–17.CrossRefPubMedPubMedCentral
64.
Bethunaickan R, Sahu R, Liu Z, Tang YT, Huang W, Edegbe O, et al. Anti-TNF treatment of IFN induced lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. Arthritis Rheum. 2012;
65.
Ondee T, Surawut S, Taratummarat S, Hirankarn N, Palaga T, Pisitkun P, et al. Fc gamma receptor IIB deficient mice: a lupus model with increased endotoxin tolerance-related sepsis susceptibility. Shock (Augusta, Ga). 2017;47(6):743–52.CrossRef
66.
• Iwata Y, Bostrom EA, Menke J, Rabacal WA, Morel L, Wada T, et al. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol. 2012;188(9):4568–80. This study describes how transient injury can lead to defective repair, nonresolving inflammation, and early onset lupus nephritis due to defective healing by aberrant macrophages in lupus prone mice.CrossRefPubMedPubMedCentral
67.
Zhang W, Xu W, Xiong S. Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol. 2010;184(11):6465–78.CrossRefPubMed
68.
Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cellular physiology and biochemistry: international journal of experimental 2015;37(4):1279–1288.
69.
Sung SJ, Ge Y, Dai C, Wang H, SM F, Sharma R, et al. Dependence of glomerulonephritis induction on novel intraglomerular alternatively activated bone marrow-derived macrophages and mac-1 and PD-L1 in lupus-prone NZM2328 mice. J Immunol. 2017;198(7):2589–601.CrossRefPubMed
70.
Kadiombo AT, Maeshima A, Kayakabe K, Ikeuchi H, Sakairi T, Kaneko Y, et al. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice. Am J Physiol Renal Physiol. 2017;312(2):F297–f304.CrossRefPubMed
71.
• Olmes G, Buttner-Herold M, Ferrazzi F, Distel L, Amann K, Daniel C. CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther. 2016;18:90. This study describes M2-like macrophages to be the dominant subpopulation in human lupus nephritis, where particularly M2a subpopulations were associated with disease progression.CrossRefPubMedPubMedCentral
72.
Li J, YF Y, Liu CH, Wang CM. Significance of M2 macrophages in glomerulonephritis with crescents. Pathol Res Pract. 2017;213(9):1215–20.CrossRefPubMed
73.
Li J, Liu CH, DL X, Gao B. Significance of CD163-positive macrophages in proliferative glomerulonephritis. Am J Med Sci. 2015;350(5):387–92.CrossRefPubMed
74.
Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008;180(3):1938–47.CrossRefPubMedPubMedCentral
Metadata
Title
Renal Macrophages and Dendritic Cells in SLE Nephritis
Authors
Naomi I. Maria
Anne Davidson
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 12/2017
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-017-0708-y

Other articles of this Issue 12/2017

Current Rheumatology Reports 12/2017 Go to the issue

Rheumatoid Arthritis (L Moreland, Section Editor)

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts

Systemic Lupus Erythematosus (G Tsokos, Section Editor)

B Cell-Based Treatments in SLE: Past Experience and Current Directions

Orphan Diseases (B Manger, Section Editor)

Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment

Pediatric Rheumatology (S Ozen, Section Editor)

Clinical Outcome and Long-term Remission in JIA

Chronic Pain (R Staud, Section Editor)

Can positive affect attenuate (persistent) pain? State of the art and clinical implications

Osteoarthritis (M Goldring, Section Editor)

The Microbiome and Bone and Joint Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits